# Defining Predictors of RT Response to Vedolizumab in IBD

> **NCT03142321** · PHASE4 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 48 (actual)

## Conditions studied

- Crohn Disease of Small Intestine

## Interventions

- **DRUG:** Vedolizumab 300 MG Injection [Entyvio]

## Key facts

- **NCT ID:** NCT03142321
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-08
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-10-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03142321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03142321, "Defining Predictors of RT Response to Vedolizumab in IBD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03142321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*